Asset Details
Do you wish to reserve the book?
Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
Do you wish to request the book?
Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of Glutaredoxin-1 and Glutathionylation in Cardiovascular Diseases
2020
Overview
Cardiovascular diseases are the leading cause of death worldwide, and as rates continue to increase, discovering mechanisms and therapeutic targets become increasingly important. An underlying cause of most cardiovascular diseases is believed to be excess reactive oxygen or nitrogen species. Glutathione, the most abundant cellular antioxidant, plays an important role in the body’s reaction to oxidative stress by forming reversible disulfide bridges with a variety of proteins, termed glutathionylation (GSylation). GSylation can alter the activity, function, and structure of proteins, making it a major regulator of cellular processes. Glutathione-protein mixed disulfide bonds are regulated by glutaredoxins (Glrxs), thioltransferase members of the thioredoxin family. Glrxs reduce GSylated proteins and make them available for another redox signaling cycle. Glrxs and GSylation play an important role in cardiovascular diseases, such as myocardial ischemia and reperfusion, cardiac hypertrophy, peripheral arterial disease, and atherosclerosis. This review primarily concerns the role of GSylation and Glrxs, particularly glutaredoxin-1 (Glrx), in cardiovascular diseases and the potential of Glrx as therapeutic agents.
Publisher
MDPI
Subject
/ Cardiovascular Diseases - drug therapy
/ Cardiovascular Diseases - metabolism
/ Cysteine - analogs & derivatives
/ Endothelial Cells - metabolism
/ Glutaredoxins - therapeutic use
/ Humans
/ Lipid Metabolism - physiology
/ Mice
/ Myocytes, Cardiac - metabolism
/ Protein Processing, Post-Translational
/ Reactive Nitrogen Species - metabolism
/ Reactive Oxygen Species - metabolism
/ Review
